Opinion on Therapy Area in South and Central America

Published within

« | ... | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Medivation: Dimebon ever closer to Alzheimer's market

Medivation is set to announce trial data regarding behavioral symptoms and the impact on caregivers relating to its Alzheimer's disease drug, Dimebon. Positive findings will enhance the validity of the impressive Phase II clinical trial data published in 2007. Dimebon is forecast for a 2011 launch, and is expected to account for 15% ($1.5 billion) of the $9.5 billion AD market by 2017.

Published By Datamonitor
14 Mar 2008
CommentWire
CommentWire

MAP Pharmaceuticals/AstraZeneca: setback for budesonide

Having signed an agreement to jointly develop Unit Dose Budesonide, Map Pharmaceuticals' novel formulation of nebulized budesonide, AstraZeneca had hoped to negate a key competitive threat while adding to its own portfolio. However, recent study results suggest that AstraZeneca's strategy may have been in vain, while the consequences may be more far reaching for MAP.

Published By Datamonitor
25 Feb 2009
ResearchWire
ResearchWire

Major depressive disorder: potential high sales for GSK's pipeline drug

Published By Datamonitor
02 Apr 2007
ResearchWire
ResearchWire

Major depressive disorder: growth markets

Published By Datamonitor
26 Sep 2007
ResearchWire
ResearchWire

mAbs: new asthma therapies to drive the market

Published By Datamonitor
23 Jun 2006
ResearchWire
ResearchWire

Lung cancer: a targeted pipeline

Published By Datamonitor
11 May 2006
ResearchWire
ResearchWire

Lung cancer market: opportunities exist for targeting rarer tumor types

Published By Datamonitor
28 Mar 2007
Expert View
Expert View

Lilly's Phase III data for solanezumab disappoint yet tantalize

Solanezumab has failed to meet its primary endpoints in two pivotal Phase III studies in Alzheimer's disease. Significantly, however, efficacy signals were discovered in prespecified secondary analyses. This suggests that Lilly's drug - widely expected to fail completely - may still have a potential path to market, pending discussions with regulators and further clinical trials.

Published By Datamonitor
28 Aug 2012
ResearchWire
ResearchWire

Kidney transplants: operation numbers climb but organ gap still widening

Published By Datamonitor
26 Apr 2006
Expert View
Expert View

J&J/Crucell: influenza deal signals shifts in the wider flu market

Johnson & Johnson and Crucell have entered into an agreement to develop and commercialize Crucell's universal influenza antibodies for the treatment and prevention of influenza. The deal strengthens Johnson & Johnson's presence in infectious diseases and gives it its first foothold in vaccines. Moreover, the deal is indicative of healthcare firms' increasing interest in influenza vaccines.

Published By Datamonitor
01 Oct 2009

« | ... | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | ... | » »|

No help is available.